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Abstract
Stroke is one of the leading causes of death worldwide. A strong inflammatory response characterized by activation
and release of cytokines, chemokines, adhesion molecules, and proteolytic enzymes contributes to brain damage
following stroke. Stroke outcomes are worse among diabetics, resulting in increased mortality and disabilities. Diabetes
involves chronic inflammation manifested by reactive oxygen species generation, expression of proinflammatory
cytokines, and activation/expression of other inflammatory mediators. It appears that increased proinflammatory
processes due to diabetes are further accelerated after cerebral ischemia, leading to increased ischemic damage.
Hypoglycemia is an intrinsic side effect owing to glucose-lowering therapy in diabetics, and is known to induce
proinflammatory changes as well as exacerbate cerebral damage in experimental stroke. Here, we present a review of
available literature on the contribution of neuroinflammation to increased cerebral ischemic damage in diabetics. We
also describe the role of hypoglycemia in neuroinflammation and cerebral ischemic damage in diabetics.
Understanding the role of neuroinflammatory mechanisms in worsening stroke outcome in diabetics may help limit
ischemic brain injury and improve clinical outcomes.




Diabetes is one of the most important metabolic dis-
orders for public health owing to the increased preva-
lence of diabetes cases worldwide. According to the
International Diabetes Federation, there are 382 mil-
lion people living with diabetes worldwide [1]. The
World Health Organization estimates that in 2030,
diabetes will be the seventh leading cause of death
[2]. Diabetes occur due to insufficient production of
insulin or/and improper action of insulin (http://
www.who.int/mediacentre/factsheets/fs312/en/) (http://
www.who.int/mediacentre/factsheets/fs312/en/). Type 1
and type 2 are the major types of diabetes (http://
www.who.int/mediacentre/factsheets/fs312/en/). Type 1
diabetes (T1D) is characterized by loss of pancreatic β cells
whereas type 2 diabetes (T2D) is the consequence of
decreased insulin response (resistance) which in later
stages is accompanied by failure of pancreatic β cells [3, 4].
Glucose-lowering drugs and risk of hypoglycemia
During the last decades, the intensive use of insulin or
other drugs, which stimulates insulin secretion, as the
main treatment to prevent hyperglycemia and its long-
term complications has resulted in an increase in the
incidence of hypoglycemia in diabetic patients [5]. An
intensively treated individual with T1D can experience
up to 10 episodes of symptomatic hypoglycemia per
week and severe temporarily disabling hypoglycemia at
least once a year (reviewed in [6]). In addition, an
impaired counter-regulatory response results in frequent
episodes of hypoglycemia in diabetic patients [7, 8].
However, hypoglycemia becomes progressively more fre-
quent, depending upon the history of hypoglycemia and
the duration of insulin treatment [9, 10]. Hypoglycemia
is estimated to account for about 2–4% of deaths in T1D
patients [11]. In a study among young patients with
T1D, continuous glucose monitoring (CGM) has
revealed frequent and prolonged asymptomatic (glucose
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<65 mg/dl) hypoglycemia in almost 70% of patients [12].
A similar study in relatively older T1D patients observed
that these patients experience hypoglycemia (glucose
≤70 mg/dl) for an average of 60–89 min/day, or 4–6% of
the time [13].
The increased prevalence of hypoglycemia has also
been noticed in a more recent study on T2D using the
CGM system [14]. In this study on 108 T2D patients
were monitored for 5 days, CGM system revealed that
49% of patients had a mean of 1.74 episodes/patient
during observation period and 75% of those patients
experienced at least one asymptomatic hypoglycemic
episode during observation period. High prevalence of
hypoglycemia (82% had at least one hypoglycemic
event) has been noticed by another study that moni-
tored T2D patients for 72-h monitoring using the CGM
system [15]. T2D patients are known to suffer from
several episodes of asymptomatic hypoglycemia every
week, symptomatic hypoglycemia as frequently as twice
per week, and experience one episode of severe (epi-
sodes that require assistance of another individual)
hypoglycemia per year [16].
Hypoglycemia is a threatening condition, as normal
brain functioning is highly dependent on a continuous
supply of glucose from the blood [17]. Episodes of
hypoglycemia can include symptoms such as warmth,
weakness and fatigue, difficulty in thinking, confusion,
behavioral changes, and emotional lability. Seizures
and loss of consciousness are observed during severe
hypoglycemia. In more severe cases, brain damage and
even death are possible [17].
The most common cause of hypoglycemia is intensive
glycemic control, the involuntary intake of excessive
doses of insulin or other glucose-decreasing drugs, or
hypoglycemia unawareness [16]. Skipping meals, eating
smaller meals, and having an irregular eating pattern are
also known risk factors for hypoglycemia. Children with
T1D are at higher risk of hypoglycemia due to difficulty
in insulin dosing, unpredictable activity and eating pat-
terns, and limitations in detecting hypoglycemia in this
population [18]. Variety of other factors such as aging,
patients with vascular disease or renal failure, pregnant
women, and young T1D patients also contributes to the
high risk of hypoglycemia [5, 18]. In T2D individuals,
the risk of hypoglycemia gradually increases due to
progressive insulin deficiency, longer duration of dia-
betes, and tight glycemic control (reviewed in [19]).
Hypoglycemia is known to cause neurologic deficits ran-
ging from reversible focal deficits to irreversible coma.
The associated neurologic deficits can be attributed to
cerebral “excitotoxic” neuropathologies, where neurons
selectively die due to an extracellular overflow of excita-
tory amino acids produced by the brain itself [20, 21].
Severe hypoglycemia can lead to brain damage when
accompanied by the silencing of the brain activity (elec-
troencephalographic isoelectricity or hypoglycemic
coma) [22, 23]. Impairment in learning and memory has
been reported in animals suffering from hypoglycemic
coma, which correlates with neuronal damage in the
hippocampus [24]. Cognitive dysfunction has also been
reported in diabetic children and adults with poor gly-
cemic control after experiencing acute hypoglycemia
[25–28]. Although moderate hypoglycemia is not life-
threatening, if recurrent, it may have serious clinical impli-
cations. The presence of oxidative stress and neuronal
death during hypoglycemia has been documented previ-
ously by several investigators [29–31]. Hypoglycemia can
also activate inflammation by increasing the plasma level
of P-selectin, an adhesion molecule that is activated by in-
flammation [32].
Diabetes and secondary complications
Long-term diabetes results in secondary complications
of diabetes. Many health issues stem from this disease
including heart disease, increased risk of stroke,
hypoglycemia, vision loss, kidney failure, amputations,
and complications within the central nervous system
(CNS) (reviewed in detail in [33, 34]). Manifestations of
diabetes-induced CNS complications may include struc-
tural alterations or brain atrophy, as well as changes in
electrophysiological properties that ultimately result in
deficits in cognitive performance [35].
Diabetes and risk of cerebral ischemia
Diabetes increases the risk of cerebral ischemia either by
ischemic stroke or cardiovascular diseases (CVD) [36, 37].
In most animal studies, acute hyperglycemia immediately
before or during ischemia exacerbates the ischemic brain
injury [38–41]. Meta-analysis of prospective studies
showed a hazard ratio of 2.27 for ischemic stroke in
diabetics compared to non-diabetics [42]. Diabetes and
diabetes-associated risk factors contribute to atherosclerotic
changes in the heart and the cerebropetal arteries. They
are also associated with an increased risk of different
subtypes of ischemic stroke (including lacunar, large
artery occlusive, and thromboembolic strokes) [43–45].
Meta-analysis of prospective cohort and case-control
studies of diabetes and risk of atrial fibrillation showed
that diabetes is associated with an increased risk of sub-
sequent atrial fibrillation, which is a major cause of
thromboembolic stroke. The risk is increased by 40% in
individuals with diabetes [46].
Diabetes and aggravation of cerebral ischemic damage
Ischemic stroke results from the obstruction of blood
flow of an artery within the brain, leading to cell death
and infarction accounting for about 87% of all strokes [47].
Ischemia leads to irreversible brain damage. In addition,
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hypoglycemia and diabetes have been reported to aggra-
vate damage following cerebrovascular disorder owing to
the involvement of many deleterious pathways including
oxidative stress, impaired leukocyte function, abnormal
angiogenesis, increased blood–brain barrier (BBB) per-
meability, and inflammatory responses [48–53]. Elevated
proinflammatory cytokines tumor necrosis factor-α
(TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and
interferon-γ (IFN-γ) as well as altered activation of macro-
phages, T cells, natural killer cells, and other immune cell
populations are associated with major comorbidities
(including diabetes) (Figs. 1 and 2) for stroke [54].
Thus, it is important to understand how neuroinflam-
matory mediators following hypoglycemia and diabetes-
associated cerebral ischemia produce irreversible CNS
injury. This will provide a basis for the development of
effective therapies to minimize the extent of damage and
improve clinical outcomes.
Mechanisms of cerebral ischemic damage
The lack of oxygen and glucose during ischemia acti-
vates an array of pathways, including bioenergetics failure,
loss of cell ion homeostasis, acidosis, increased intracel-
lular calcium levels, glutamate excitotoxicity, reactive
oxygen species (ROS)-mediated toxicity, generation of
arachidonic acid products, cytokine-mediated cytotoxicity,
activation of neuronal nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) and glial cells,
complement activation, disruption of the BBB, and
infiltration of leukocytes [55, 56]. Ischemia-induced
glutamate excitotoxicity is a pathogenic process that
can lead to calcium-mediated neuronal injury and death
by generating ROS and nitrogen species, as well as
impairing mitochondrial bioenergetic function [57–59].
The resulting oxidative stress causes further damage
and may ultimately result in the initiation of pathways
that lead to necrotic and apoptotic cell death.
Fig. 1 Schematic representation of neuroinflammatory mechanisms involved in aggravating brain damage following cerebral ischemia under
hyperglycemic/hypoglycemic conditions
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Mechanisms of damage following cerebral
ischemia
Apoptosis
The process of programmed cell death, apoptosis, acts as
a defense mechanism to remove damaged, unwanted, or
potentially harmful cells. Apoptosis is also termed type I
programmed cell death (type I PCD) [60] and is charac-
terized by nuclear condensation and fragmentation,
cleavage of chromosomal deoxyribonucleic acid (DNA)
into internucleosomal fragments, and the formation of
apoptotic bodies. These apoptotic bodies are removed by
phagocytosis [61]. Apoptosis after cerebral ischemia can
occur via intrinsic and extrinsic pathways. The intrinsic
pathway is initiated by disruption of mitochondria and
secretion of cytochrome C which leads to caspase
activation which subsequently leads to apoptotic cell
death (reviewed in detail in [62]).
The extrinsic pathway involves cell surface receptors
and ligands that lead to cell death. Forkhead1, a member
of the forkhead family of transcription factors, stimulates
the expression of target genes, e.g., Fas ligands (FasL),
which are implicated in the extrinsic receptor pathway
of caspase 3 activation. FasL binds to Fas death receptors
(FasR), which triggers the recruitment of the Fas-
associated death domain protein (FADD). FADD binds
to procaspase-8 to create a death-inducing signaling cas-
cade (DISC), which activates caspase 8. Activated
caspase-8 either mediates cleavage of BH3 interacting-
domain death agonist (Bid) to truncated Bid (tBid),
which integrates the different death pathways at the
Fig. 2 Detailed schematic representation of neuroinflammatory mechanisms involved in aggravating brain damage following cerebral ischemia in
diabetes (hyperglycemic and hypoglycemic conditions)
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mitochondrial checkpoint of apoptosis, or directly acti-
vates caspase-3. At the mitochondrial membrane, tBid
interacts with Bcl-2 (B cell lymphoma-2)-associated X
protein (Bax). Dimerization of tBid and Bax leads to the
opening of mitochondrial transition pore, thereby releasing
cytochrome C, which initiates caspase 3-dependent
cell death (reviewed in detail in [62]).
Necrosis
Necrosis is another major pathway of cell death observed
following cerebral ischemia. Morphological characteristics
of necrosis include vacuolation of the cytoplasm, break-
down of the plasma membrane, and induction of inflam-
mation around the dying cell by release of cellular
contents including lysosomes and proinflammatory mole-
cules [61]. Necrotic cell death in ischemic brain injury
occurs via poly(adenosine diphosphate (ADP)-ribose)-
polymerase (PARP) and/or calpains. PARP-1 activity
following cerebral ischemic injury is high. Absence or
inhibition of PARP-1 is shown to lower cerebral ischemic
damage in in vivo and in vitro models of cerebral ischemia
and/or excitotoxicity [63, 64]. An increased intracellular
free Ca2+ level activates multiple Ca2+-dependent enzymes
such as neutral cysteine proteases and calpains [65]. The
excessive activation of calpain-induced cytoskeletal
protein breakdown leads to structural integrity and dis-
turbances of axonal transport, and finally to necrotic
cell death [66]. Reduced cerebral ischemic damage with
the calpain inhibitor, Cbz-Val-Phe-H, confirms the role
of calpain in cerebral ischemic damage [67].
Other mechanisms of cell death
Autophagy, a third type of cell death, also contributes to
cerebral ischemic damage [68, 69]. Autophagy is also
known as type II PCD [70]. An association between
autophagy and injury has been demonstrated in experi-
mental model of stroke by Wen et al. [71]. In their
study, 3-methyladenine (3-MA; an autophagy inhibitor)
treatment significantly lowered infarct volume, brain
edema, and motor deficits. These neuroprotective effects
were associated with an inhibition of ischemia-induced
upregulation of light chain 3-II (LC3-II)—a marker of
active autophagosomes and autophagolysosomes. An-
other study observed that inhibition of autophagy,
either by direct inhibitor 3-MA or by indirect inhibitor
2-methoxyestradiol (2ME2) (an inhibitor of hypoxia
inducible factor-1α (HIF-1α)) prevented pyramidal
neuron death after ischemia [72]. Mice deficient in
autophagy-related gene (Atg)7, the gene essential for
autophagy induction, showed nearly complete protec-
tion against hypoxia-ischemia-induced neuronal death,
indicating autophagy as one of the important mechanisms
of cell death following hypoxia–ischemia [73]. All these
studies demonstrated involvement of autophagy in cere-
bral ischemic damage.
Neuroinflammatory mechanism of cell death
following cerebral ischemia
Cellular mediators of inflammation
After cerebral ischemia, neuroinflammation occurs, which
is characterized by the accumulation of inflammatory cells
and other mediators in the ischemic brain from resident
brain cells (activated microglia/macrophages, astrocytes)
and infiltrating immune cells (leukocytes). Which subse-
quently leads to inflammatory injury.
Leukocytes/macrophages
The recruitment of leukocytes from the circulation into
the extravascular space in the brain is a central feature
after ischemia/reperfusion (I/R). The leukocyte popula-
tion primarily consists of neutrophils, monocytes, and
lymphocytes, each of which can contribute to inflamma-
tion following ischemia (reviewed in detail in [74]).
Monocytes transform into blood-borne macrophages
upon activation. Macrophages play a dual role after
cerebral ischemia owing to expressions of anti- and pro-
inflammatory mediators. Macrophages exert neurotoxic
effects by creating prothrombotic and proinflammatory
environment via the release of platelet-activating fac-
tor, proinflammatory cytokines (TNF-α, IL-1β), and
superoxide anions [75]. The macrophages also confer
beneficial effects by removing damaged cells via
phagocytosis [76, 77].
Microglia
Microglia are modulators of the immune response in the
brain [78, 79]. Once activated, these cells are indistin-
guishable from circulating macrophages [80]. Activated
microglia eliminates foreign organisms by means of
phagocytosis. However, microglia when activated fol-
lowing ischemia contributes to ischemic injury via pro-
duction of neuroinflammatory mediators toxic to cells
(reviewed in detail in [74, 81]).
Astrocytes
Astrocytic activation represents a potentially damaging
mechanism following cerebral ischemia by producing
inflammatory mediators and cytotoxic molecules such as
ROS, nitrogen species, and proteases, among others
[82]. Overall, astrocytic activation is involved in damaging
consequences following cerebral ischemia.
Neuroinflammatory response after cerebral ischemia
Cerebral ischemia leads to the activation of microglia
and astrocytes as well as mobilization and infiltration of
peripheral inflammatory cells into the brain. The develop-
ment of post-ischemic brain inflammation is coordinated
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by activation, expression, and secretions of numerous pro-
inflammatory mediators such as cytokines, chemokines,
and adhesion molecules from the brain parenchyma and
vascular cells, all of which contribute to increased vul-
nerability of neurons, and causes BBB disruption and
further stimulates gliosis, which further leads to cell
damage and ultimately death [74, 81]. Lowering ische-
mic damage by targeting neuroinflammatory pathways
is considered one of the important areas of research in
recent years.
Cytokines
Cytokines are inflammatory mediators produced by
leukocytes, macrophages, endothelial cells, and resident
cells within the CNS, including glial cells and neurons,
in response to a diverse range of injuries. Following
cerebral I/R, altered expression of proinflammatory and
anti-inflammatory cytokines worsens tissue pathology.
Anti-inflammatory cytokines Interleukin-10 (IL-10):
IL-10 inhibits interleukin-1β (IL-1β), TNF-α, and
interleukin-8 (IL-8) as well as lowers cytokine receptor
expression and receptor activation [83]. Animal studies
have confirmed the anticipated neuroprotective role of
this anti-inflammatory cytokine in ischemic stroke [84–
86]. In in vitro models, IL-10 protects murine cortical
and cerebellar neurons from excitotoxic damage and oxy-
gen/glucose deprivation by activating survival pathways
[85, 87]. Clinically, lower IL-10 plasma levels have been
associated with increased risk of stroke [88]. Collectively,
these studies suggest that IL-10 is neuroprotective
through indirect effects on proinflammatory pathways.
Transforming growth factor -β (TGF-β): TGF-β1 has
been regarded as an important endogenous mediator
that responds to ischemic injury in the CNS [89–91].
Studies have shown neuroprotective activity of TGF-β1
against ischemia [92–95]. One recent report demon-
strated the anti-inflammatory effect of TGF-β by inhi-
biting excessive neuroinflammation during the sub-acute
phase of brain ischemia [96]. Intra-carotid administration
of TGF-β has been shown to reduce the number of
circulating neutrophils, which may ameliorate the
post-ischemic no-reflow state [97]. TGF-β may also
reduce neutrophil adherence to endothelial cells, sup-
presses the release of potentially harmful oxygen- and
nitrogen-derived products, promotes angiogenesis in
the penumbral area, and reduces the expression and
efficacy of other cytokines such as TNF-α [98]. Thus,
knowing the exact mechanisms involved behind neu-
roprotection played by these anti-inflammatory cyto-
kines may lead to more effective therapies that limit
brain injury during ischemia.
Proinflammatory cytokines Interleukin-1 (IL-1):
Interleukin-1 is a major mediator of the inflammatory
response following ischemia, with potentially neurotoxic
effects. There are two isoforms, IL-1α and IL-1β. IL-1
receptor antagonist (IL-1ra) is an endogenous inhibitor
of IL-1 [99, 100]. Post-ischemic increase in the levels of
IL-1β correlates with larger infarct size. Intraventricular
injection of recombinant IL-1β enlarged infarct volume
and brain edema as well as increased influx of neutro-
phils after middle cerebral artery occlusion (MCAO)
[101]. The deleterious effects of IL-1 were also demon-
strated by Garcia et al [102] and Relton et al [103] who
showed that administration of recombinant IL-1 recep-
tor antagonist reduces the severity of neurologic deficits
and tissue necrosis in rats subjected to permanent
MCAO. The inhibition of IL-1β signaling with IL-1ra
has been found to be protective in experimental models
of stroke [104]. Recombinant human IL-1 receptor
antagonist (rhIL-1ra) was well tolerated and appeared to
be safe when administered within 6 h of acute stroke in
a clinical trial [105]. IL-1, and in particular, IL-1β plays
an important role in brain injury during ischemia. Thus,
modulating IL-1β expression may help to reduce the
exacerbation of IL-1β-induced ischemic injury.
Tumor necrosis factor-α (TNF-α): TNF-α is a well-
known inflammatory factor associated with worsened
clinical outcomes after stroke and exacerbations of
infarct size in pre-clinical models [106, 107]. TNF-α is
increased in the serum of stroke patients between 6 and
12 h after symptom onset [108, 109]. TNF-α levels in
cerebrospinal fluid (CSF) and serum of patients with
ischemic stroke were markedly increased within 24 h,
and this increase in levels of CSF and serum TNF-α was
positively correlated with infarct volume [110]. Like IL-1,
TNF-α induces adhesion molecule expression in cerebral
endothelial cells and promotes neutrophil accumulation
and transmigration. In addition, TNF-α stimulates acute-
phase protein production, disrupts the BBB, and stimu-
lates the induction of other inflammatory mediators [111].
TNF-α is a pleiotropic cytokine that possesses both
neurotoxic and neuroprotective effects [112]. TNF-α is
believed to have detrimental roles during the early phase of
the inflammatory response while beneficial roles in the later
stages [113]. On one hand, blockade of TNF-α reduces
infarct volume after permanent MCAO [106]. Similarly, the
anti-TNF-α antibody Pl14 and the TNF synthesis inhibitor
CNI-1493 also improve behavioral deficits in Lewis rats
after stroke [114]. Treatment with the PARP inhibitor PJ34
[115], the proteosome inhibitor MLN519 [116], or the tree-
derived compound brazilien [117] is associated with
reduced brain TNF-α expression after transient MCAO. All
these experimental manipulations reduce the area of infarct
and neurological deficits. This indicates a deleterious role
of TNF-α in stroke progression in these animal models.
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On the other hand, TNF-α pretreatment is neuropro-
tective against permanent MCAO [118]. Knockout mice
deficient in TNF-α receptors have enhanced sensitivity
to stroke, with exacerbated neuronal damage [119].
TNF-α can also mediate neuroprotection in other situa-
tions. In one study, sodium nitroprusside was used to
induce acute nitric oxide excitotoxicity in TNF-α
knockout mice. These mice showed dramatic exacerbation
of neuronal damage, suggesting that early endogenous
TNF-α release after the insult is neuroprotective [120]. In
another study, TNF-α-expressing neurons from TNF-α-
transgenic mice were strongly protected from apoptosis
induced by glutamate, a substance inducing excitotoxicity
in primary cortical neurons. Neurons from wild-type mice
pretreated with TNF-α were also resistant to excitotoxicity
[121]. Further, excitotoxic neuronal death induced by
N-methyl-D-aspartate (NMDA) is reduced by TNF-α
treatment in cultured cortical neurons [122]. Thus, the
neurotoxic and neuroprotective effect of TNF-α depends
on several factors such as cellular source, activation of
TNF-α receptors, timing and threshold of TNF-α released,
and factors that stimulate TNF-α signaling.
Interleukin-6 (IL-6): IL-6 is a pleiotropic cytokine. It is
unclear whether the overall effect of IL-6 is beneficial or
detrimental following cerebral ischemia. The IL-6 level
remains elevated starting at 4 h to 2 weeks post ischemia
with the peak at 24 h post ischemia [113, 123, 124]. IL-6
stimulates T lymphocyte proliferation and infiltration
into the brain leading to increased inflammatory
response. However, IL-6 does not contribute to ischemic
brain injury as IL-6 can upregulate IL-1ra, and lack of
IL-6 (deficient mice) does not affect post-ischemic out-
come [125, 126]. Thus, it is unclear whether the overall
effect of IL-6 is beneficial or detrimental in the context
of stroke, although in clinical studies, serum levels of
IL-6 were suggested as a good predictor of in-hospital
mortality in patients that had suffered an acute ischemic
stroke [127]. Also, high plasma IL-6 levels correlate with
the severity of stroke [128].
Chemokines
The chemokines are the members of the G-protein-
coupled receptor superfamily and are classified by position
of cysteine residues [129]. Chemokines and chemokine
receptors have been found to be upregulated following
ischemia and signal leukocytes to traffic on the inflamed
cerebral endothelium [130]. Upregulated expression of
several chemokines and their receptors including, C-C
motif chemokine ligand-2/monocyte chemoattractant
protein-1(CCL-2/MCP-1), C-C motif chemokine ligand-3/
macrophage inflammatory protein-1 α (CCL-3/MIP-1α),
C-C motif chemokine ligand-5/regulated on activation,
normal T cell expressed and secreted (CCL-5/RANTES),
C-C motif chemokine ligand-7 (CCL-7), C-X-C motif
chemokine ligand-10/interferon inducible protein-10;
(CXCL-10/IP-10), C-C motif chemokine ligand-20
(CCL-20), and chemokine receptors C-X-C motif chemo-
kine receptor-4 (CXCR-4) and C-C motif chemokine
receptor-6 (CCR-6) following ischemia have been reported
earlier [131–136].
Post-ischemic increase in production and release of
chemokines (e.g., cytokine-induced neutrophil chemo-
attractant: CINC, MCP-1, Fracktalkine, macrophage
inflammatory protein: MIP-1, etc.), which is suggested to
be stimulated by cytokines (especially IL-1β, TNF-α, and
IL-6), is responsible for regulation and migration of
monocytes, neutrophils, and lymphocytes at the site of
inflammation [137–144]. In rats, administration of anti-
CINC antibody decreases cerebral edema and infarction,
which further supports a role for CINC in mediating
neutrophils and demonstrates another therapeutic
opportunity [145].
Inhibition of chemokines during ischemic injury is
associated with improved outcomes [146], while over-
expression of chemokines exacerbates injury through
increased recruitment of inflammatory cells [130]. Previ-
ous studies have reported that chemokine or chemokine
receptor inhibition or deficiency can decrease ischemic
brain injury. MCP-1 deficiency in genetically altered mice
and the blockade of chemokine receptors, using non-
peptide C-C chemokine receptor antagonist TAK-779,
modulated inflammatory responses in the CNS result-
ing in reduced infarct volume and macrophage accu-
mulation in a stroke model [147, 148], respectively. It
has been shown that anti-MCP-1-neutralizing antibody
attenuated NMDA-induced brain injury in the striatum
and hippocampus [149]. Intracerebroventricular adminis-
tration of anti-MIP-3α neutralizing antibody reduces
transient MCAO-induced infarct size [134]. A pharma-
cological inhibitor of C-X-C motif chemokine ligand-8
(CXCL-8), repertaxin, is neuroprotective in a rodent
model of transient brain ischemia and its beneficial ef-
fects have been attributed to the inhibition of neutro-
phil recruitment and decreased secondary injury [146].
Inhibition of C-X-C motif chemokine receptor-1
(CXCR-1)/-2 receptors by reparixin (acting as a non-
competitive allosteric antagonist of the CXCR-1 and
CXCR-2 receptors) protected the brain after MCAO
[150]. After 24 h of reperfusion, pretreatment with
reparixin significantly reduced myeloperoxidase (MPO)
activity and reduced the levels of IL-1β [150]. The admin-
istration of SB225002, a CXCR-2 antagonist, was also
associated with reduced neutrophil infiltration in the
brains of rats 24 h after cerebral I/R, but did not im-
prove outcome. Mice treated with either SB225002 or
vehicle had similar motor impairment and infarct
volume at 72 h [151]. C-X3-C motif chemokine recep-
tor-1(CX3CR-1) deficiency correlates with improved
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neurological function following MCAO and suggests that
blockade of CX3CR-1/C-X3-C motif chemokine ligand-1
signaling may provide neuroprotection against ischemic
injury. In regard to acute CNS injury models (transient
and permanent brain ischemia, spinal cord injury), the
collective data suggest that the absence of CX3CR-1 sig-
nificantly reduces ischemic damage and inflammation
[152–154]. The ability of chemokines to control precisely
the movement of inflammatory cells suggests that chemo-
kines and their receptors might provide novel targets for
CNS therapeutic intervention.
Matrix metalloproteinases (MMPs)
The MMPs are zinc- and calcium-dependent endopepti-
dases, identified as matrix-degrading enzymes. MMP-9-
and MMP-2-mediated disruption of BBB integrity and
neuronal cell death has been suggested following cere-
bral ischemia [155, 156]. Treatment with MMP-9 in-
hibitor within 24 h of stroke reduced infarct size at day
14, and this benefit was lost when the treatment was
delayed until 72 h. Further delayed in the treatment
(until day 7 post-stroke) exacerbated brain pathology
[157]. Additionally, broad-spectrum MMP inhibitors
such as BB-94 and BB-1101 have been shown to reduce
infarct size and restore BBB integrity in rodent stroke
models [158, 159]. Although prolonged inhibition of
MMP-9 was found to be detrimental to the late recovery
phase of stroke [160, 161]. MMP-2 and MMP-9 selective
inhibitor SB-3CT reduced infarct size when administered
at 6 h of ischemia onset [162]. In human ischemic stroke,
active MMP-2 is increased first on days 2–5 compared to
active MMP-9, which is elevated up to months after the
ischemic episode [163]. The increased plasma MMP-9
level and the presence of MMP-9 in human brain sections
after both ischemic and hemorrhagic stroke further sup-
port a role for MMP-9 in the pathophysiology of stroke
[163, 164]. The available literature suggests that future
therapeutics targeting specific MMP inhibition might be
beneficial in ischemic stroke.
Cell adhesion molecules
Cell adhesion molecules (CAM) are cell-surface proteins
that mediate cell–cell and cell–extracellular matrix inter-
actions [165]. Adhesion molecules play a crucial role in
the pathophysiology of acute ischemic stroke [166]. The
three main groups of CAMs: the selectins, the immuno-
globulin gene superfamily, and the integrins play main
role in leukocytes and the vascular endothelium inter-
action [167].
Selectins: Selectins are membrane-bound glycoproteins
that are necessary for the initial capture and rolling of
leukocytes on the vessel wall during inflammation [168].
There are three selectins, i.e., L- (leukocyte), E- (endo-
thelial), and P- (platelet) selectins and all of them share
a common sequence and structural features [169]. Selec-
tins once activated binds with carbohydrate residues
[sialyl-LewisX (sLeX)] and participates in tethering
and rolling of circulating leukocytes on endothelium.
Dysregulated selectin expression contributes to the
inflammation [168].
Leukocyte adhesion has been demonstrated in different
experimental models of cerebral ischemia and hypoxia
[170, 171]. Although L-selectins mediate the initial rolling
of leukocytes, their exact involvement in the development
of ischemic injury is not known. Blockade of L-selectin
with a humanized anti-L-selectin antibody did not lessen
the extent of leukocyte adhesion and transmigration into
the areas of damage in a rabbit model of transient focal
cerebral ischemia [172]. In another study using cerebral I/
R model, anti-L-selectin antibodies were found to be ef-
fective only when used in combination with tissue plas-
minogen activators (tPA), which addresses the potential
involvement of L-selectin in tissue injury following
thrombolytic reperfusion of the ischemic brain [173].
Following cerebral ischemia, P- and E-selectins are
highly expressed in the brain. P-selectin can be detected
as early as 15 min after reperfusion while E-selectin ex-
pression is observed beginning at 2 h after ischemia. The
expression of selectins contributes to the early recruit-
ment of circulating cells to the infarct region [174], and
blocking their function has neuroprotective effects in
certain stroke models [175, 176]. Anti-selectin antibodies
or a synthetic analog of sLeX lowers damage following
cerebral ischemia [177, 178]. In a model of cerebral I/R,
P-selectin knockout mice exhibited a reduction in infarct
volume, better functional outcome, and a better return
of cerebral blood flow after ischemia [179]. In a per-
manent ischemia model, P-selectin immunoblockade
attenuated both infarct size and brain edema, which
were associated with a reduction of leukocyte infiltration
[180]. In these studies, the anti-P-selectin antibodies were
administered 30 min before the ischemic insult, which
lessens the therapeutic value of the observed protection.
Overall, it is suggested that antagonizing selectin using
either anti-selectin antibodies or anti-selectin peptides
is effective in reducing stroke volume.
Immunoglobulin (Ig) superfamily: The immunoglobulin
superfamily class of cell adhesion molecules mediates the
adhesion of leukocytes to endothelial cells. In terms of
leukocyte–endothelial interactions, the Ig superfamily
consists of five molecules: intercellular adhesion molecule
(ICAM)-1 and ICAM-2, vascular cell adhesion molecule
(VCAM)-1, platelet–endothelial cell adhesion molecule-1
(PECAM-1), and mucosal addressin cell adhesion
molecule-1 (MAdCAM-1) [181]. After cerebral ischemia,
ICAM-1, ICAM-2, VCAM-1, and PECAM-1 have been
shown to contribute to the inflammatory response
[182, 183]. ICAM-1 expression is an essential step in
Shukla et al. Journal of Neuroinflammation  (2017) 14:21 Page 8 of 22
mediating the firm adhesion of leukocytes in cerebral
microvessels after ischemic stroke, and there are sev-
eral studies that address the contribution of ICAM-1 to
cerebral injury after stroke [184–188]. Immunoneutraliza-
tion or genetic deletion of cell adhesion molecules that
mediate leukocyte recruitment reduces tissue injury and
brain dysfunction in animal models of focal and global
cerebral ischemia (reviewed in [166]).
Studies have shown that ICAM-1-deficient mice have
smaller infarcts compared to wild-type mice following
focal cerebral ischemia [184, 185]. Similarly, ICAM-1
immunoblockade reduces ischemic brain injury and
neutrophil accumulation in both rat and rabbit models
of cerebral ischemia [186–188]. These findings help
emphasize the critical role of leukocyte adhesion in fur-
thering inflammatory injury following cerebral ische-
mia. A significant reduction in ischemic lesion was
observed in anti-ICAM-1 antibody-treated or ICAM-1
antisense oligonucleotide-treated group following tran-
sient MCAO [189, 190].
VCAM-1 is upregulated following stimulation by cyto-
kines (i.e., IL-1 and TNF-α) [191]. However, the role of
VCAM-1 in inflammatory injury is not completely
understood. Inhibition of VCAM-1 expression was neu-
roprotective in a model of transient global cerebral
ischemia [192], while inhibition of VCAM-1 was not
neuroprotective in a focal cerebral ischemia model [193].
Increased plasma and CSF concentrations of soluble
ICAM-1 (sICAM-1) and soluble VCAM-1 (sVCAM-1)
were measureable in patients shortly following cerebral
ischemic events and these concentrations correlated
with the severity of injury [194, 195]. Thus, we conclude
that future studies involving anti-adhesion therapies in
ischemic stroke will provide promising strategies in
modulating adhesion properties of post-ischemic cere-
bral microvasculature and thereby limit brain injury.
Integrins: The integrins respond to a variety of inflam-
matory mediators, including cytokines, chemokines, and
chemoattractants [196]. Integrins are transmembrane
surface proteins that consist of a common β-subunit
dimerized with a variable α-subunit (cluster of differen-
tiation (CD)11a, CD11b, or CD11c) [197]. The CD11a/
CD18 integrin is referred as lymphocyte function-
associated antigen-1 (LFA-1), whereas CD11b/CD18 is
called leukocyte adhesion receptor macrophage-1 antigen
(Mac-1). Upregulated LFA-1 and Mac-1 expression con-
tribute to the severity of ischemic stroke. Mice deficient in
Mac-1 showed reduced infarct volume and reduced neu-
trophil extravasation after cerebral ischemia [198–200].
Blocking CD11b [200, 201] as well as CD18 [202] or both
[203, 204] reduces injury from experimental stroke and is
associated with decreased neutrophil infiltration. Similarly,
mice lacking CD18 exhibited reduced leukocyte adhesion
to endothelial cell monolayers and improved cerebral
blood flow with less neurological injury and neutrophil
accumulation when subjected to experimental stroke
[205]. Blocking integrins essential for lymphocyte and
monocyte trafficking may also limit damage due to reper-
fusion injury.
Clinical studies examined the potential of anti-integrin
therapies in acute stroke patients. In a phase III trial,
stroke patients were treated with humanized anti-Mac-1
antibody (LeukArrest), the first dose within 12 h while
the second dose at 60 h post-symptom onset [206].
Another trial was a phase IIb dose escalation study of a
non-antibody peptide, recombinant neutrophil inhibiting
factor (rNIF) in stroke patients (Acute Stroke Therapy
by Inhibition of Neutrophils or ASTIN) administered
within 6 h of symptom onset [207]. Both studies were
terminated prematurely owing to a lack of effect on pre-
determined endpoints. In a rabbit model of transient
focal ischemia, administration of LeukArrest 20 min post
ischemia decreased neutrophil infiltration and reduced
neuronal injury (52% reduction) [76, 204]. No beneficial
effect was observed in models of permanent stroke
[76, 208]. Anti-adhesion molecule strategies using
integrins as targets in ischemic stroke have proven
more effective following transient, but not permanent
ischemia [189, 205, 209].
Toll-like receptors (TLRs)
TLRs are a family of pattern recognition receptors that
were initially identified for their role in the activation of
innate immunity in response to the presence of exogenous
microorganisms; however, TLRs also play a role in ische-
mic injury in the absence of infection [210]. In this setting,
TLRs recognize endogenous molecules released during
injury. Such endogenous molecules are known as
damage-associated molecular patterns (DAMPs). The
binding of DAMPs to their respective receptors results
in the activation of an inflammatory response that can
exacerbate ischemic damage [210]. Upregulated TLRs
levels associated with enhanced cell damage and their
inhibition/blockade correlated with reduced infarct size
following ischemia [211–214]. The involvement of
TLRs and their ligands in inflammation-induced neuronal
injury following cerebral ischemia is widely reported
[111, 211–216]. TLR-4-deficient mice showed reduced
infarct size, better outcomes in neurological and behav-
ioral tests, and decreased level of inflammatory mediators
following experimental stroke [217–219]. TLR-2 and the
TLR-4 mutant mice showed significantly smaller post-
stroke brain damage and lower neurological impairments
compared with wild-type mice [220]. Thus, modulating
TLR-2 and TLR-4 levels protects the brain against
ischemia-induced neuronal damage. Clinical studies have
also examined the role of TLRs in stroke patients, in-
cluding those that focus on the association of TLR-4
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polymorphisms with the prevalence of stroke [221, 222].
Thus, TLRs appear to be involved in ischemic injury both
in experimental models and in clinical studies. These
could be potential targets for future studies focusing on
therapeutic approach.
Diabetes and hypoglycemia
Severe hypoglycemia is considered a medical emergency
as it causes organ and brain damage. The types of
symptoms that depend on duration and severity of
hypoglycemia includes autonomic symptoms (sweating,
irritability, and tremulousness), cognitive impairment,
seizures, and coma. Brain damage, trauma, cardiovascular
complications, and death are major complications of
severe hypoglycemia [223]. The incidence of hypoglycemia
depends on the degree of glycemic control. Threefold
increase in incidences of severe hypoglycemia and coma
in intensively treated group was observed when compared
to conventionally treated group in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study [224].
The risk of hypoglycemia in randomized controlled
trials of glucose regulation in stroke settings has been
reported ranging from 7 to 76% [225–230]. The ische-
mic brain is particularly susceptible to hypoglycemia
[231]. In the presence of stroke, it is possible that inci-
dents of hypoglycemia may be mistaken for progressing
severity of stroke, given that symptoms of hypoglycemia
include impaired cognitive functioning, hemiparesis,
seizures, and coma.
Hypoglycemia is proposed to be linked with angina,
myocardial infarction, and acute CVD [232–234].
Hypoglycemia causes a cascade of physiologic effects
and may induce oxidative stress [235], induce cardiac
arrhythmias [236], contribute to sudden cardiac death
[236], and cause cerebral ischemic damage [237], pre-
senting several potential mechanisms through which
acute and chronic episodes of hypoglycemia may
increase CVD risk.
Increased levels of C-reactive protein (CRP), IL-6, IL-8,
TNF-α, and endothelin-1 have been shown during
hypoglycemia [238, 239]. Wright et al. [240] and Gogitidze
Joy et al. [32] confirmed that hypoglycemia induced an in-
crease in proinflammatory mediators and platelet acti-
vation, and has an inhibitory effect on fibrinolytic
mechanisms. Hypoglycemia also increases production
of vascular endothelial growth factor (VEGF), increases
platelet and neutrophil activation leading to endothelial
dysfunction, and decreased vasodilation, resulting in in-
creased risk for CVD events [241]. Furthermore, IL-1
has been shown to increase the severity of hypoglycemia
[242]. Moderate hypoglycemia acutely increases circulat-
ing levels of plasminogen activator inhibitor-1 (PAI-1),
VEGF, vascular adhesion molecules (VCAM, ICAM,
E-selectin), IL-6, and markers of platelet activation
(P-selectin) in T1D patients and healthy individuals
[32]. Thus, hypoglycemia can result in complex vas-
cular effects including activation of prothrombotic,
proinflammatory, and proatherogenic mechanisms in
T1D patients and healthy individuals. In addition, a
link has been made between low glucose levels and
the unexpected sudden death in T1D patients without
CVD, also known as “dead in bed” syndrome [243].
Recurrent severe hypoglycemia results in brain damage
[244], with preferential vulnerability in the cerebral cortex
and hippocampus [244–246]. Evidence suggests that
neuronal damage resulting from hypoglycemia is
enhanced in diabetic compared to non-diabetic brains
[245]. Hypoglycemia causes a loss of ionic homeostasis
or increase in ROS that can further lead to neuronal
inflammation and death [246].
Impact of hypoglycemia in the diabetic brain
Hypoglycemia is of major concern in diabetes as it leads
to severe impairment of CNS function. Severe and/or
long duration hypoglycemia may result in severe morbidity
and even death. Repeated episodes of hypoglycemia are
suggested to increase the risk of atherosclerosis [247].
Acute hypoglycemia results in endothelial dysfunction,
vasoconstriction, white blood cell activation, and release of
inflammatory mediators including cytokines via sym-
pathoadrenal stimulation and release of counter-regulatory
hormones [32]. All these changes increase the risk of myo-
cardial and cerebral ischemia [240].
Recurrent/moderate hypoglycemia also aggravates
post-ischemic brain damage in diabetic rats [53]. In this
study, rats treated with insulin and exposed to recurrent
hypoglycemic episodes experienced a 44% increase in
neuronal death compared with rats similarly treated with
insulin but not exposed to hypoglycemia, demonstrating
that prior exposure to recurrent hypoglycemia can lead
to more extensive cerebral ischemic damage. Relatively
severe recurrent hypoglycemia itself induces neuronal death
in the CA1 hippocampus and cortex of streptozotocin-
induced diabetic rats [248, 249].
Bree and collaborators [245] showed that insulin-
induced severe hypoglycemia in normal animals elicits
brain damage in the cortex, cornus ammonis (CA)1, and
CA3 hippocampal regions, and that the diabetic condi-
tion increases the vulnerability to neuronal death in
these specific brain areas. These results suggest that
diabetes can be a critical factor aggravating neuronal
damage in hypoglycemia.
Decreased cognitive function can also lead to an in-
creased risk of hypoglycemia and CVD events, and thus
mortality [250]. In a study examining magnetic resonance
imaging of the brain in a cohort of 22 patients with T1D,
brain abnormalities were more common in patients with
T1D who had a history of repeated (five or more)
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hypoglycemic episodes [251]. In some of the strongest evi-
dence to date of the detrimental effects of hypoglycemia
on cognitive function, Whitmer et al. [252] investigated
the association of hospitalization or emergency depart-
ment visits for hypoglycemia and dementia development
in older adults with T2D. They reported a dose/response
relationship between the number of hypoglycemia epi-
sodes and the risk for developing dementia.
Inflammatory response in diabetes/hyperglycemia
Increased systemic and cerebrovascular inflammation is
one of the key pathophysiological features in diabetes
and its vascular complications [253, 254]. Though the
etiology of diabetic complications is multifactorial, chronic
inflammation is thought to play a critical role [255, 256].
Key mechanisms of hyperglycemia-induced inflammation
include NFkB-dependent production of proinflammatory
cytokines, TLR expression, increased oxidative stress, and
inflammasome activation [256–259].
Increased expression of proinflammatory cytokines has
been demonstrated in diabetes (reviewed in [260]). Pro-
inflammatory cytokines IL-12 and IL-18 were shown to
be elevated in serum of diabetic patients compared to
healthy subjects and were positively associated with CRP,
which is one of the most important biomarkers of
chronic inflammation [261, 262]. CRP itself exerts direct
proinflammatory effects on human endothelial cells,
inducing the expression of adhesion molecules [263].
IL-12 and IL-18 have been shown to exert strong pro-
inflammatory activity that synergize with each other, as
well as with TNF-α or IL-1 [264]. NFκB controls the
induction of many inflammatory genes. During hyper-
glycemia, NFκB is rapidly and dramatically activated in
vascular cells resulting in a subsequent increase in
leukocyte adhesion and transcription of proinflamma-
tory cytokines [41]. A significant increase in expression
of proinflammatory cytokines (TNF-α, IL-6, and IL-1β),
followed by activation of NFkB and signal transducer acti-
vator of transcription 3 (STAT3) inflammatory pathways,
was reported in cultured astrocytes treated with high glu-
cose [265]. Under diabetic conditions, hyperglycemia also
causes inflammatory reactions in other organs and tissues
in vivo [266, 267]. It has been reported that high glucose
in vitro can cause ROS production and expression of pro-
inflammatory cytokines and chemokines in a variety of
cells [268–270]. Expression of adhesion molecules on
endothelial cells of both hyperglycemic and diabetic ani-
mals, and patients with diabetes, is enhanced compared to
normal controls [271].
TLRs play an important role in human and animal
model of diabetes. Mice with an inactive TLR-4 gene
were significantly less prone to diet-induced insulin re-
sistance [272, 273]. Likewise, inhibition of TLR-2 func-
tion in mice exposed to a high-fat diet led to improved
sensitivity and decreased activation of proinflammatory
pathways [274]. Furthermore, polymorphisms in TLRs and
in members of TLR downstream signaling pathways that
encode hyper- or hypoactive responses predict the develop-
ment of T1D and T2D [275, 276]. TLR ligands activate B
cell cytokine production, most significantly IL-8, in diabetes
mellitus vs. non-diabetic donors [277]. The circulating
levels of danger molecules including the high-mobility
group box-1 (HMGB-1), heat shock proteins, and hyaluro-
nan that activates TLR signals [278] are known to be in-
creased in T2D patients [258]. Potential roles for TLR-2
and TLR-4 in the pathology of diabetes have been
demonstrated recently (reviewed in detail in [279]).
Emerging evidence suggests that activation of the
nucleotide-binding and oligomerization domain-like re-
ceptor family pyrin domain-containing 3 (NLRP3)
inflammasome leads to the maturation and secretion of
IL-1β and is involved in the pathogenic mechanisms of
obesity-induced inflammation, insulin resistance, and
diabetes development [280]. Obesity-induced danger sig-
nals have been reported to activate the NLRP3 inflam-
masome and induce the production of IL-1β in adipose
tissue in T2D patients and in mice fed a high-fat diet
[281]. Circulating levels of CXCL-10 and CCL-2, as well
as IFN-γ mRNA (messenger ribonucleic acid) and pro-
tein levels in adipose tissue were significantly reduced in
NLRP3-deficient mice, suggesting that the NLRP3
inflammasome plays a role in the macrophage-T cell in-
teractions that are associated with sustained levels of
chronic inflammation in obesity-induced metabolic dis-
eases [281]. Moreover, the saturated fatty acid palmitate
induces activation of the NLRP3 inflammasome in
hematopoietic cells, which is responsible for the im-
pairment of insulin signaling and inhibition of glucose
tolerance in mice [282].
Inflammatory response in hypoglycemia
Recurrent/moderate hypoglycemia induces oxidative in-
jury in hippocampal dendrites, and microglial activation
in hippocampus and cerebral cortex [248]. They ob-
served oxidative damage, as assessed by the lipoperoxi-
dation product 4-hidroxynonenal, in the hippocampal
CA1 dendritic layer and microglial activation. The degree
of microglial activation in the hippocampus of recurrent/
moderate hypoglycemia-exposed diabetic rats was 194%
higher than in normoglycemic rats exposed to recurrent/
moderate hypoglycemia [248]. This study confirmed that
inflammatory responses are also induced after recurrent/
moderate hypoglycemia. Microglial activation is induced in
severe hypoglycemia and contributes to neuronal injury by
releasing neurotoxic substances, including superoxide, ni-
tric oxide, and metalloproteinases [283–285]. Activation
of microglia appears to play a role in the neutrophil
infiltration and recruitment which in turn contributes
Shukla et al. Journal of Neuroinflammation  (2017) 14:21 Page 11 of 22
to brain damage [286, 287]. Increased number of infil-
trating neutrophils in hypoglycemia vulnerable brain
regions following hypoglycemic brain injury suggests its
potential role in hypoglycemic brain injury [288].
In another study by Cardoso et al. [289], recurrent
hypoglycemia (twice daily for 2 weeks) in streptozotocin-
induced diabetic rats potentiated an increase in lipid
peroxidation and a decrease in aconitase activity, used
as an index of oxidative stress, in mitochondria from
diabetic animals. Previous findings showed that recur-
rent hypoglycemia differentially alters mitochondrial
bioenergetics and the antioxidant defense response in
the cortex and the hippocampus, the hippocampus
being most affected. Limiting ROS production and
restoring blood glucose to levels not exceeding the
physiological range prevents neuronal death [31]. On
the other hand, the administration of pyruvate and lac-
tate in combination with glucose reduces the death of
hippocampal neurons [288, 290, 291]. This finding sug-
gests the therapeutic potential of antioxidants, lactate,
and pyruvate administration combined with glucose to
limit the adverse consequences of glucose reperfusion.
On the other hand, it has been recently shown that the
administration of minocycline to rats 6 h after
hypoglycemic coma and daily for a week results in
reduced microglial reactivity, neuronal death, and cog-
nitive impairment [288]. Further investigation is needed
to extrapolate these findings to clinical practice.
Cerebral ischemia-induced inflammatory response
in the diabetic brain
Diabetes continues to expand rapidly in the USA.
Worldwide, it is projected that diabetes will affect 439
million people by the year 2030 [292]. As mentioned
above, diabetes is a predisposing risk factor for cerebro-
vascular diseases and increases stroke incidence. In
humans, diabetes increases the risk of stroke incidence
as well as post-stroke mortality [293–295]. Diabetes
duration has also been shown to increase the risk of is-
chemic stroke. With every year of diabetes, the risk is
increased by 3% and triples with diabetes of more than
10 years [296]. Diabetes predisposes humans to stroke,
and stroke-induced brain damage is known to be exac-
erbated by poor functional recovery in these patients
[297]. Several clinical studies indicated that patients
with diabetes had poorer outcomes following stroke
[298–302].
Diabetic patients have a higher risk of stroke com-
pared with non-diabetic patients [294, 295]. Although
>30% of stroke sufferers are known to be diabetic, the
mechanisms that are responsible for the increased post-
ischemic brain damage in this population are understudied.
Oxidative stress and inflammation play a central role in tis-
sue damage in streptozotocin-induced diabetes [303, 304].
In addition, diabetic patients had significantly increased
levels of acute phase proteins and proinflammatory cyto-
kines such as TNF-α and IL-1, compared to non-diabetic
controls [305]. More recently, Hwang et al. [306] demon-
strated microglial activation and expression of proinflam-
matory cytokines, such as IFN-γ and IL-1β in the
hippocampus of diabetic rats.
The experimental studies have evaluated the effect of
diabetes on stroke outcome in T1D and T2D models.
The post-ischemic brain damage was exacerbated in
T1D rodents following global or focal ischemia [52, 297,
307–310]. The exacerbated edema and infarction, wors-
ened neurological status, and increased mortality have
also been observed in T2D models following ischemia
[311–314]. A study by Yeung et al. showed that exacer-
bated post-ischemic pathological symptoms observed in
db/db mice are alleviated by knocking out the enzyme of
polyol pathway (aldose reductase) that converts glucose
to sorbitol and further metabolizes to fructose [315].
Uncontrolled inflammation during the acute period after
stroke is a major mediator of cerebrovascular failure and
brain damage [316]. Increased expression of cell adhe-
sion molecules enabling the extravasation of white blood
cells, and further induction of proinflammatory tran-
scription factors and other inflammatory genes are
thought to be major mediators of post-ischemic inflam-
mation [74]. Previously published literature demonstrated
the increased expression of ICAM and proinflammatory
cytokines in diabetic animals after cerebral ischemia/re-
perfusion [317–320]. At post-translational levels, IL-1β
and cyclooxygenase-2 (COX-2) expressions were signifi-
cantly higher following hyperglycemic ischemia than
hyperglycemic shams [321]. Lin et al. demonstrated that
hyperglycemia triggered early, massive deposition of neu-
trophils in the post-ischemic brain, which exacerbated
injury [322]. It has been reported that the expression of
ICAM-1 and the infiltration of neutrophils into ischemic
tissue are closely correlated with the severity of ischemic
brain damage [323]. The gene expression of IL-1β, IL-6,
MIP-1α, MCP-1, P-selectin, and E-selectin was much
higher in the diabetic mouse brain compared to normo-
glycemic mouse brain at 12 h of reperfusion following
transient MCAO [52]. In another study, diabetic rats had
an increased basal level of IL-1β and TNF-α, and inflam-
matory mediators COX-2 and inducible nitric oxide
synthase (iNOS) expressions as compared to that of
non-diabetic rats. Transient MCAO increased the gene
expression of these cytokines and enzymes, which was
remarkably accelerated and augmented by diabetes
[324]. Furthermore, this group showed increased
expression of MPO and ICAM-1, which are hallmarks
of neutrophil, and macrophage/microglia activation and
exacerbation in the diabetic rat brain, indicating exacer-
bation of inflammatory responses in ischemic injury
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[324]. Enhanced activation of NFκB in the diabetic
brain mediated this increased production of proinflam-
matory cytokines and enzymes [324]. NFκB is a potent
inducer of inflammatory processes through its upregu-
lation of the gene expression of proinflammatory cyto-
kines and chemokines such as IL-1β, IL-6, interleukin-17
(IL-17), TNF-α, CRPs, MCP-1, CCL-2, and CXC [325].
The transcription factor NFκB assumes a key role in cere-
bral ischemia and regulates apoptosis and inflammation
[326]. Thus, activation of NFκB is crucial for the inflam-
matory responses leading to gene expression of proinflam-
matory cytokines and mediators in immunocytes [326].
Inhibition of NFκB represents a treatment strategy in
ischemic stroke [327].
Thus, the exacerbated inflammation might be a con-
tributing factor to the increased post-stroke brain damage
observed in the diabetic brain (Figs. 1 and 2). Further-
more, the macrophages and neutrophils release oxygen
and nitrogen free radicals which are extremely toxic to
neurons. Studies indicate that the extent of stroke-
induced brain injury is influenced by the systemic inflam-
mation. It has been shown that increased peripheral
inflammation, at the time of stroke, aggravates ische-
mic injury [328]. Diabetic mice are known to manifest
systemic inflammation as well as impaired ability to
curtail inflammation [329]. Several proinflammatory
proteins including MCP-1 and IL-6 are elevated in the
plasma of diabetic patients [330, 331]. The critical role
of MCP-1 in the diabetic condition has been demon-
strated in studies showing that its overexpression in
adipocytes leads to tissue inflammation and insulin re-
sistance, while mice deficient in MCP-1 or its receptor
C-C motif chemokine receptor-2 (CCR-2) reverse the
condition [332–334]. More recently, Kim et al. [335]
demonstrated that in the diabetic condition, acute inflam-
matory responses are perturbed in the brain following
stroke and in the macrophages after lipopolysaccharide
stimulation, and these alterations are associated with the
exacerbation of stroke-induced injury [335]. Interestingly,
diabetic mice were found to display reduced inflammatory
cytokine expression and microglial activation, and delayed
wound healing [312]. Microglial activation and the release
of chemokines and cytokines are critical steps in eliciting
inflammatory responses. The inability to mount a proper
host immune response immediately after cerebral ische-
mia in diabetic microglia causes an extended inflamma-
tory phase, which leads to a prolonged infiltration of
peripheral immune cells and worsened ischemic injury
[335]. The early blunted inflammatory response of MCP-
1, IL-6, and CCR-2 in the diabetic mouse brain was re-
ported at 6 h post ischemia [335]. Collectively, the data
from this study suggest that early inflammatory responses
in the diabetic brain are deregulated, and the alteration is
associated with the exacerbation of stroke-induced injury.
An attenuated stroke-induced inflammatory response
has been demonstrated in diabetic conditions [312, 313].
Treatment of obese diabetic mice with the peroxisome
proliferator-activated receptor γ (PPARγ) agonist darglita-
zone, for 7 days before induction of hypoxia–ischemia,
reduced infarct size and suppressed inflammatory
response at 8 and 24 h after ischemia onset [312, 313].
Animal studies have shown that MMP plays an important
role in cerebrovascular damage following permanent focal
stroke in diabetic rats [336, 337]. A greater MMP-9 activity
was found in diabetic rats following stroke [307, 336].
HMGB-1 is a novel player in the ischemic brain [215].
Diabetes significantly increased serum HMGB level and
induced worse functional outcome after stroke com-
pared to non-diabetic rats [338]. Diabetes exacerbates
systemic inflammation as evidenced by higher serum
HMGB-1 in the rat systemic inflammation model [339].
HMGB-1 signaling promotes chemotaxis and production
of cytokines in a process that involves the activation of
NFκB [340]. Moreover, it has been reported that extra-
cellular HMGB-1 is involved in BBB disruption during
the early phase of ischemic stroke [341]. Downregulation
of HMGB-1 and NFκB expression protected rat brains
against focal ischemia. Suppression of the release of
HMGB-1 in astrocytes leads to the attenuation of neuro-
inflammation, preventing the necrosis of ischemic astro-
cytes and NFκB expression [342]. Inhibition of the
upregulation of HMGB-1 and NFκB at the early stage
brings great benefits to cerebral ischemia.
Dysregulated expression of stromal cell-derived factor
(SDF)-1α and CXCR-4 has been reported in the diabetic
mice brain at baseline and following ischemic stroke
[343]. The SDF-1α/CXCR-4 axis is believed to play an
important role in recruiting progenitor cells into ische-
mic tissue. It triggers many intracellular proliferation
and anti-apoptosis signals, such as mitogen-activated
protein kinase (MAPK), phosphatidylinositol 3-kinase
(PI3K), and the serine/threonine Kinase Akt [344].
Therefore, SDF-1α/CXCR-4 is a potential target for pro-
moting repair in wound and ischemic injury.
Overall, diabetes and hypoglycemia aggravates brain
damage after ischemic stroke through enhancement of
the neuroinflammatory signaling cascade, particularly by
the activation of microglia/macrophages, leukocytes,
adhesion molecules, upregulation/accumulation of some
specific proinflammatory cytokines, MMPs, TLRs, and
other immune mediators at the site of injury. All these
immune mediators directly or indirectly contribute to
further activation of cell death pathways (Figs. 1 and 2).
Conclusions
Diabetes is a crucial risk factor for stroke. Stroke out-
comes are significantly worse among diabetic patients,
resulting in increased mortality as well as neurological
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and functional disabilities. Stroke risk in patients with
diabetes is two- to sixfold higher than age-matched
controls. Increased incidence of hypoglycemia is the in-
evitable effect of treatment for aggressively tight glycemic
control in diabetes, and is prevalent among both T1D and
T2D patients. Studies have shown that diabetes and its
associated hypoglycemia exacerbate cerebral ischemic
damage in experimental animals. Understanding the
mechanisms involved in aggravating neuroinflammatory
injury following cerebral ischemia in diabetes and asso-
ciated hypoglycemia is important. Suppressing potential
candidates involved in enhancing neuroinflammatory
response may help reduce stroke severity and promote
recovery in diabetic/hypoglycemic conditions. An in-
creasing number of studies demonstrate the role of
inflammatory mediators in modulating stroke outcome
in animal models of T1D and T2D. Thus, targeting
inflammatory mediators for future therapeutic strategy
in diabetes and its associated hypoglycemic complications
appears important. Better understanding of inflammatory
pathways involved in diabetes, diabetes-associated
hypoglycemia, and diabetic cerebral ischemia may provide
unique pharmacological targets for the treatment and/or
prevention of hypoglycemia and diabetes-associated
stroke damage.
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IFN-γ: Interferon-γ; Ig: Immunoglobulin; IL-1: Interleukin-1; IL-10: Interleukin-10;
IL-17: Interleukin-17; IL-1ra: IL-1 receptor antagonist; IL-1β: Interleukin-1β;
IL-6: Interleukin-6; IL-8: Interleukin-8; iNOS: Inducible nitric oxide synthase;
IP-10: Interferon-inducible protein-10; L: Leukocyte; LC3-II: Light chain 3-II;
LFA-1: Lymphocyte function-associated antigen-1; Mac-1: Macrophage-1
antigen; MAdCAM-1: Mucosal addressin cell adhesion molecule-1;
MAPK: Mitogen-activated protein kinase; MCAO: Middle cerebral artery
occlusion; MCP-1: Monocyte chemoattractant protein-1; MHC: Major
histocompatibility complex; MIP-1: Macrophage inflammatory protein-1;
MIP-1α: Macrophage inflammatory protein-1 α; MMPs: Matrix metalloproteinases;
MPO: Myeloperoxidase; mRNA: Messenger ribonucleic acid; NFkB: Nuclear factor
kappa-light-chain-enhancer B cells; NLRP3: Nucleotide-binding and
oligomerization domain-like receptor family pyrin domain-containing 3;
NMDA: N-methyl-D-aspartate; P: Platelet; PAI-1: Plasminogen activator
inhibitor-1; PARP: Poly(ADP)-ribose-polymerase; PECAM-1: Platelet-
endothelial cell adhesion molecule-1; PI3K: Phosphatidylinositol 3-kinase;
PPARγ: Peroxisome proliferator-activated receptor γ; RANTES: Regulated
on activation, normal T cell expressed and secreted; rhIL-1Ra: Recombinant
human interleukin-1 receptor antagonist; rNIF: Recombinant neutrophil
inhibiting factor; ROS: Reactive oxygen species; SDF: Stromal cell-derived
factor; sICAM-1: Soluble ICAM-1; sLeX: Sialyl-LewisX; STAT3: Signal transducer
activator of transcription 3; sVCAM-1: Soluble VCAM-1; T1D: Type 1 diabetes;
T2D: Type 2 diabetes; tBid: Truncated Bid; TGF-β: Transforming growth factor-β;
TLRs: Toll-like receptors; TNF-α: Tumor necrosis factor-α; tPA: Tissue plasminogen
activators; type I PCD: Type I programmed cell death; VCAM: Vascular cell
adhesion molecule; VEGF: Vascular endothelial growth factor
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